Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. develops therapies for severe rare diseases and difficult-to-treat fungal infections. The company’s updates center on SCY-770, a clinical-stage oral direct AMPK activator for autosomal dominant polycystic kidney disease, and SCY-247, a second-generation triterpenoid antifungal therapy in development for invasive candidiasis and prophylaxis of invasive fungal disease.
SCYNEXIS news also covers its fungerp antifungal platform, FDA designations for SCY-247, scientific presentations, financial results, and corporate actions. The company has licensed ibrexafungerp, including BREXAFEMME® for vulvovaginal candidiasis and reduction in recurrent vulvovaginal candidiasis, to GSK, making collaboration and license-agreement updates a recurring disclosure theme.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
SCYNEXIS, a biotechnology company, has announced its presentation of interim data on various infection types from the ongoing Phase 3 FURI and CARES studies, along with the innovative MARIO trial design. This will occur at the 33rd Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 15-18, 2023, in Copenhagen, Denmark. Key presentations include:
- Oral Ibrexafungerp outcomes in urinary tract infections.
- Evaluation of Ibrexafungerp's efficacy alone and with other antifungals.
- A novel protocol for Ibrexafungerp as step-down therapy.
Ibrexafungerp, a groundbreaking antifungal agent, shows promise against drug-resistant infections. It has received FDA designations for invasive candidiasis and aspergillosis, highlighting its potential in treating difficult infections.
SCYNEXIS has secured an exclusive agreement with GSK for the commercialization and development of BREXAFEMME (ibrexafungerp), including an upfront payment of $90 million and potential future milestone payments totaling $503 million. The company retains rights to all other fungerp assets. As of Q4 2022, SCYNEXIS reported $1.4 million in net sales for BREXAFEMME with 5,125 prescriptions written. The company has completed enrollment in several Phase 2 and Phase 3 trials for ibrexafungerp and has a projected cash runway of over two years post-GSK transaction. However, net loss for 2022 was $62.8 million.